Cerus Corporation
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. William M. Greenman
- Full Time Employees
- 625
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1220 Concord Avenue Concord CA United States of America 94520
- IPO Date
- Jan 31, 1997
- CIK
- 0001020214
- Website
- cerus.com
- Similar Companies
- Business
- Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Company News
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)
Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript
Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update
Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus Corporation Announces Third Quarter 2024 Financial Results
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus Corporation (CERS) Q2 2024 Earnings Call Transcript
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
Cerus Corporation Celebrates World Blood Donor Day 2024
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Cerus Corporation (CERS) Q1 2024 Earnings Call Transcript
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients